Research Interests:

Liotta and Petricoin began their proteomics collaboration in 1997, which led to the formation of the first Interagency Agreement between NCI and FDA to develop and test technologies for proteomic analysis—the study of protein activity in cells—of cancer and other diseases. Their renowned collaboration has produced more than 100 publications and numerous proteomic processes to develop new methods for diagnosis and treatment of diseases. Combining their clinical and research expertise, they invented a new type of protein microarray technology to simultaneously measure multiple protein pathways from a biopsy specimen. Understanding the activity of protein pathways may ultimately lead to personalized medical treatment and significantly impact public health. In addition to their invention and development of new types of protein microarray technologies, they recently have made several seminal discoveries for biomarker-based research that may assist in the diagnosis of cancer and other diseases.